References
- Berkovic S F, Andermann F, Carpenter S, Wolfe L. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med 1986; 31: 296–304
- Roger J, Genton P, Bureau M, Dravet C. Progressive myoclonus epilepsies in childhood and adolescence. Epileptic Syndromes in Infancy, Childhood and Adolescence, 2nd edn, J Roger, M Bureau, C Dravet, F E Dreifuss, A Perret, P Wolf. John Libbey, London 1992; 381–400
- Marseille Consensus Group. Classification of progressive myoclonus epilepsies and related disorders. Ann Neurol 1990; 28: 113–6
- Unverricht H. Die Myoclonie. Franz Deuticke, Leipzig 1891
- Lundborg H. Die progressive Myoklonus Epilepsie (Unuerricht's Myoclonie). Almquist and Wiksell, UppsalaSweden 1903
- Lafora G R. Über das vorkommen amyloider Körperchen im innern der Ganglienzellen; zugleich ein zum Studium der amyloiden Substanz im Nervensystem. Virchows Arch Path Anat 1911; 205: 295–303
- Haltia M, Kristensson K, Sourander P. Neuropathological studies in three Scandinavian cases of progressive myoclonus epilepsy. Acta Neurol Scand 1969; 45: 63–77
- Koskiniemi M, Dormer M, Majuri H, Haltia M, Norio R. Progressive myoclonus epilepsy: a clinical and histopathologic study. Acta Neurol Scand 1974; 50: 307–32
- Koskiniemi M, Toivakka E, Donner M. Progressive myoclonus epilepsy. Electroencephalographical findings. Acta Neurol Scand 1974; 30: 33–359
- Koskiniemi M. Psychological findings in progressive myoclonus epilepsy without Lafora bodies. Epilepsia 1974; 15: 537–45
- Norio R, Koskiniemi M. Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet 1979; 15: 382–98
- Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder B J. “Baltic” myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983; 2: 838–42
- Genton P, Michelucci R, Tassinari C A, Roger J. The Ramsay Hunt syndrome revisited: Mediterranean myoclonus versus mitochondrial encephalomyopathy with ragged-red fibers and Baltic myoclonus. Acta Neurol Scand 1990; 81: 8–15
- Koskiniemi M. Baltic myoclonus. Adv Neurol 1986; 43: 57–64
- Koskiniemi M. Baltic myoclonus. Ann Clin Res 1987; 19: 311–12
- Kyllerman M, Sommerfelt T K, Hedstrom A, Wennergren G, Holmgren D. Clinical and neurophysiological development of Unverricht-Lundborg disease in four Swedish siblings. Epilepsia 1991; 32: 900–9
- Koskiniemi M. Findings in routine laboratory examination in progressive myoclonus epilepsy. Acta Neurol Scand 1975; 51: 12–20
- Koskiniemi M, Palo J. Urinary excretion of indican in progressive myoclonus epilepsy without Lafora bodies: the effect of sodium valproate. J Neurol Sci 1978; 39: 235–9
- Chadwick D, Jenner P, Reynolds E H. Serotonin metabolism in human epilepsy: the influence of anticonvulsant drugs. Ann Neurol 1977; 1: 218–24
- Leino E, MacDonald E, Airaksinen M, Riekkinen P J. Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with progressive myoclonus epilepsy. Acta Neurol Scand 1980; 62: 41–54
- Koskiniemi M, Laakso J, Harkonen M, Laipio M, Kuurne T. Indole levels in human lumbar and ventricular cerebrospinal fluid and the effect of L-tryptophan administration. Acta Neurol Scand 1985; 71: 127–37
- Hari R, Salmi T, Bergström L, Murros K. Brainstem and auditory evoked potentials in progressive myoclonus epilepsy without Lafora bodies. Acta Neurol Scand 1983; 67: 376–8
- Shibasaki H, Yamashita Y, Neshige R, Tobimatsu S, Fukui R. Pathogenesis of giant somatosensory evoked potential in progressive myoclonus epilepsy. Brain 1985; 108: 225–40
- Mervaala E, Keränen T, Päàkkönen A, Partanen J, Riekkinen P. Visual evoked potentials, brainstem auditory evoked potentials and quantitative EEG in Baltic progressive myoclonus epilepsy. Epilepsia 1986; 27: 542–7
- Reutens D C, Puce A, Berkovic S F. Cortical hyperexcitability in progressive myoclonus epilepsy. Neurology 1993; 43: 186–92
- Karhu J, Hari R, Paetau R, Kajola M, Mervaala E. Cortical reactivity in progressive myoclonus epilepsy. Electroencephalogr Clin Neurophysiol 1994; 90: 93–102
- Cochius J, Carpenter S, Andermann E, et al. Sweat gland vacuoles in Unverricht-Lundborg disease: a clue to diagnosis?. Neurology 1994; 44: 2372–5
- Harenko A, Toivakka E. Myoclonus epilepsy (Unverricht-Lundborg) in Finland. Acta Neurol Scand 1961; 37: 282–96
- Iivanainen M, Himberg J J. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 1982; 39: 236–8
- Somerville E R, Olanow W. Valproic acid. Treatment of myoclonus in dyssynergia cerebellaris myoclonica. Arch Neurol 1982; 39: 527–8
- Goldberg M A, Dorman J D. Intention myoclonus: successful treatment with clonazepam. Neurology 1976; 26: 24–6
- Chadwick D, Hallett M, Harris R, Jenner P, Reynolds E H, Marsden C D. Clinical biochemical and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 1977; 100: 455–87
- Koskiniemi M, Hyyppä M, Sainio K, Salmi T, Sarna S, Uotila L. Transient effect of L-tryptophan in progressive myoclonus epilepsy without Lafora bodies: clinical and electrophysiological study. Epilepsia 1980; 21: 351–7
- Pranzatelli M R, Tate E, Huang Y, et al. Neuropharmacology of progressive myoclonus epilepsy: response to 5-hydroxy-L-tryptophan. Epilepsia 1995; 36: 783–91
- Remy C, Genton P. Effect of high dose of oral piracetam on myoclonus in progressive myoclonus epilepsy (Mediterranean myoclonus). Epilepsia 1991; 32: 6
- Gouliaev A H, Senning A. Piracetam and other structurally related nootropics. Brain Res Rev 1994; 19: 180–222
- Koskiniemi M, Van Vleymen B, Hakamies L, Lamusuo S, Taalas J. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998; 64: 344–8
- Lehesjoki A-E, Koskiniemi M, Sistonen P, et al. Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22. Proc Natl Acad Sci USA 1991; 88: 3696–9
- Lehesjoki A-E, Koskiniemi M, Pandolfo M, et al. Linkage studies in progressive myoclonus epilepsy: Unverricht-Lundborg and Lafora diseases. Neurology 1992; 42: 1545–50
- Lehesjoki A-E, Koskiniemi M, Norio R, et al. Localization of the EPM1 gene for progressive myoclonus epilepsy on chromosome 21: linkage disequilibrium allows high resolution mapping. Hum Mol Genet 1993; 2: 1229–34
- Lehesjoki A-E, Eldridge R, Eldridge J, Wilder B J, de la Chapelle A. Progressive myoclonus epilepsy of Unverricht-Lundborg type: a clinical and molecular genetic study of a family from the United States with four affected sibs. Neurology 1993; 43: 2384–6
- de la Chapelle A. Disease gene mapping in isolated human populations: the example of Finland. J Med Genet 1993; 30: 857–65
- Virtaneva K, Miao J, Träskelin, et al. Progressive myoclonus epilepsy EPM1 locus maps to a 175 kb interval in distal 21q. Am J Hum Genet 1996; 58: 1247–53
- Stone N E, Fan J-B, Willour V, et al. Construction of a 750 kb bacterial clone contig and restriction map in the region of human chromosome 21 containing the progressive myoclonus epilepsy (EPM1) gene. Genome Res 1996; 6: 218–25
- Pennacchio L A, Lehesjoki A-E, Stone N E, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996; 271: 1731–4
- Järvinen M, Rinne A. Human spleen cysteineprotease inhibitor. Purification, fractionation into isoelectric variants and some properties of the variants. Biochim Biophys Acta 1982; 708: 210–17
- Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 1991; 285: 213–9
- Jerala R, Trstenjak M, Lenarcic Turk V. Cloning a synthetic-gene for human stefin B and its expression in E. coli. FEBS Lett 1988; 239: 41–4
- Ritonja A, Machleidt W, Barrett A J. Amino acid sequence of the intracellular cysteine proteinase inhibitor cystatin B from human liver. Biochem Biophys Res Commun 1985; 131: 1187–92
- Lalioti M D, Mirotsou M, Buresi C, et al. Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). Am J Hum Genet 1997; 60: 342–51
- Lafreniere R G, Rochefort D L, Chretien N, et al. Unstable insertion in the 5′-flanking region of the cystatin-B gene is the most common mutation in progressive myoclonus epilepsy type-1, EPM1. Nat Genet 1997; 15: 298–302
- Virtaneva K, D'Amato E, Miao J, et al. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet 1997; 15: 393–6
- Lalioti M D, Scott H S, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 1997; 386: 847–51
- Lalioti M D, Scott H S, Antonarakis S E. What is expanded in progressive myoclonus epilepsy?. Nat Genet 1997; 17: 17
- Virtaneva K, Paulin L, Krahe R, de la Chapelle A, Lehesjoki A-E. The minisatellite expansion mutation in EPM1: resolution of an initial discrepancy. Hum Mutat 1998; 12: 218
- Warren S T. The expanding world of trinucleotide repeats. Science 1996; 271: 1374–5
- Lalioti M D, Scott H S, Genton P, et al. A PCR amplification method reveals instability of the dodecamer repeat in progressive myoclonus epilepsy (EPM1) and no correlation between the size of the repeat and age at onset. Am J Hum Genet 1998; 62: 842–47
- Roger J, Soulayrol R, Hassoun J. La dyssynergie cerebelleuse myoclonique (syndrome de Ramsay Hunt). Rev Neurol 1968; 119: 85–106
- Tassinari C A, Michelucci R, Genton P, Pellissier J F, Roger J. Dyssynergia cerebellaris myoclonica (Ramsay Hunt syndrome): a condition unrelated to mitochondrial encephalomyopathies. J Neurol Neurosurg Psychiatry 1989; 52: 262–5
- Malafosse A, Lehesjoki A-E, Genton P, Laubauge P. Identical genetic locus for Baltic and Mediterranean myoclonus. Lancet 1992; 339: 1080–1
- Lehesjoki A-E, Tassinari C A, Avanzini G, et al. PME of Unverricht-Lundborg type in the Mediterranean region: linkage and linkage disequilibrium confirm the assignment to the EPM1 locus. Hum Genet 1994; 93: 668–74